Laurel Anne Menapace MD (She/Her)

PubMed

• Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.
  Steven W Pipe, Toshko Lissitchkov, Pencho Georgiev, Sarah Mangles, Inga Hegemann
  Blood Advances. 2025-03-11
• Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.
  Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi
  Blood. 2025-03-07
• 41 citations
  A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
  Julia Z Xu, Anna Conrey, Ingrid Frey, Eveline Gwaabe, Laurel A Menapace
  Blood. 2022-11-10

Books/Book Chapters

• Hematology Basic Principles and Practice 
  Chapter: Clinical Aspects of Sickle Cell Disease 
  Laurel A. Menapace, Swee Lay TheinEditors: Ronald Hoffman, Edward J. Benz, Leslie E. Silberstein, Helen Heslop, Jeffrey Weitz, Mohamed E. Salama.Elsevier Health SciencesEdition 8th,2022

Abstracts/Posters

• Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regim...
  Steven W. Pipe, Kaan Kavakli, Tadashi Matsushita, Huyen Tran, Bulent Zulfikar, Laurel Menapace, Marja Puurunen, Wenruo Hu, Yuqian Shen, Chanchala Kaddi and Vanessa Sal..., ASH 2024 Annual Meeting Oral Presentation and Abstract, San Diego, CA, 12/7/2024
• Incidence of Thrombotic Events in the Fitusiran Clinical Development Program
  Guy Young, David Matino, Steven Pipe, Laurel A Menapace, Yuqian Shen et al, ISTH 2024 Annual Meeting Oral Communication and Abstract, Bangkok, Thailand, 6/24/2024
• Surgical Experience in People with Hemophilia A or B With and Without Inhibitors Receiving Fitusiran
  Alok Srivastava, Pencho Georgiev, Toshko Lissitchkov, Margaret V. Ragni, Laurel A. Menapace, et al, ISTH 2024 Annual Meeting Oral Communication and Abstract, Bangkok, Thailand, 6/23/2024
• The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the ...
  Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Me..., ASH 2022 Annual Meeting Poster Abstract, New Orleans, LA, 12/15/2022
• A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune Mediated Thrombotic Thrombocyt...
  Sriya Gunawardena, Angela Hu, Laurel A. Menapace, Hikaru Okada, Beverly Accomando, Julie Lin, ASH 2022 Annual Meeting Poster Abstract, New Orleans, LA, 12/10/2022
• Mitapivat (AG-348) Demonstrates Safety, Tolerability and Improvements in Anemia, Hemolysis, Oxygen Affinity and Hemoglobin S Polymerization Kinetics in Adults with Sic...
  ulia Z. Xu, Anna Conrey, Ingrid Frey, Eveline Gwaabe, Laurel A Menapace, Laxminath Tumburu, Maureen Lundt, Quan Li et al, ASH 2021 Annual Meeting Oral Presentation and Abstract, Atlanta, GA, 12/7/2021
• Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease
  Julia Z. Xu, Anna Conrey, Ingrid Frey, Jim Nichols, Laurel A. Menapace, Laxminath Tumburu, Timothy Lequang, Quan Li, Emily B. Dunkelberger, Eric R. Henry, Troy Cellmer..., 62nd American Society of Hematology Annual Meeting Oral Abstract, San Diego, CA, 12/7/2020
• Botanical Product Use Among Multiple Myeloma Patients in Commercial Drug Trials
  Laurel A Menapace, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Career-Development Lunch Sessions: Government Careers (NIH) 
  60th American Society of Hematology Annual Meeting - 12/1/2018